In vivo studies demonstrated that XL-MSNs co-delivered antigen peptide and TLR9 agonists could effectively target draining lymph nodes, induce tumor infiltration of antigen-specific cytotoxic T lymphocytes (CTL), and inhibit tumor growth. The gene discussed is TLR9; the disease is neoplasm.